HomeAI · summaries
Storia in 3 fonti
Nearly 1 in 5 patients quit Boehringer and Zealand’s obesity shot over side effects
Boehringer's survodutide showed 19% GI discontinuation rates in a Phase 3 obesity trial but was on par with Wegovy on weight loss.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Pfizer's good-enough obesity data in a crowded market may force competition on price, dosing
Pfizer's berobenatide shows up to 10.2% weight loss and 2.2% blood sugar reduction in Phase 2b trial in patients with obesity and type 2 diabetes.
- ·
thehindubusinessline.com
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Pfizer's monthly obesity shot, berobenatide, shows similar side effects to Wegovy, aiming for differentiation in the weight-loss market.
